Clinical Trial Update: Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating ticagrelor to reduce graft events and thrombosis in patients with saphenous vein graft disease has completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Saphenous Vein Graft Disease

Drugs mentioned

• TICAGRELOR (ticagrelor)

Snippet

Sponsor: Boca Raton Regional Hospital | Conditions: Saphenous Vein Graft Disease | Phase 4 | Status: COMPLETED | Results posted: 2022-09-14